Ronald D. Perrone

1 month ago | healio.com | Shawn M. Carter |Gina Brockenbrough |Ronald D. Perrone

Key takeaways: Patients on tolvaptan had an eGFR decline of 1.40 mL/min/1.73 m² per year. Annual rate of eGFR decline in patients on tolvaptan was slower than in historical controls. Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney disease compared with historical controls, data show.